Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…
BTIG Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $29
BTIG analyst Julian Harrison maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $32 to $29.
HC Wainwright & Co. Maintains Buy on Aclaris Therapeutics, Lowers Price Target to $43
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Buy and lowers the price target from $50 to $43.
Nasdaq Rises 50 Points; Ciena Earnings Top Expectations
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining around 50 points on Monday.
The Dow traded up 0.16% to 33,444.91 while the NASDAQ rose 0.43% to 11,739.11. The S&P 500 also rose, gaining, 0.35% to 4,059.80.
Dow Jumps Over 100 Points; BridgeBio Pharma Shares Spike Higher
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 100 points on Monday.
The Dow traded up 0.42% to 33,531.77 while the NASDAQ rose 0.97% to 11,802.73. The S&P 500 also rose, gaining, 0.69% to 4,073.40.
Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target
Cantor Fitzgerald analyst Louise Chen reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and maintains $38 price target.
Benzinga’s Top Ratings Upgrades, Downgrades For December 1, 2022
Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55…
Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25
Goldman Sachs analyst Corinne Jenkins initiates coverage on Aclaris Therapeutics (NASDAQ:ACRS) with a Buy rating and announces Price Target of $25.
Aclaris Therapeutics Announces Key Leadership Transitions; Douglas Manion, M.D. Appointed To Succeed Dr. Walker As CEO And Appointed To The Board Of Directors; Kevin Balthaser Appointed CFO To Succeed Retiring Frank Ruffo
- Dr. Neal Walker to transition to Chair of the Board of Directors
- Current Board Chair Christopher Molineaux to become Lead Independent Director
- Douglas Manion, M.D. appointed to succeed Dr. Walker as Chief
